Strong Profits, Stronger Growth – Cipher Pharmaceutical (CPH:TSX) Soars Nearly 300% | $CPH

Cipher Pharmaceuticals (CPH:TSX) has been one of the top-performing Canadian pharma stocks, with CPH stock soaring nearly 300% since 2023. In this video, Brett breaks down the latest CPH Q2 results, highlighting revenue growth of 152%, EBITDA growth of 148%, and an 81% profit margin. This Cipher Pharmaceuticals analysis looks at how this small cap pharma stock is disrupting the market with Netroba, its growth strategy in Canada and the U.S., and what it means for investors.

Submit a Company to be Featured: https://keystocks.com/YSOT
Find all things Keystone at https://keystocks.com/

Socials:
Twitter: https://x.com/KeyStocks
Facebook: https://www.facebook.com/keystocks
LinkedIn: https://www.linkedin.com/company/keystocks/
Instagram: https://www.instagram.com/keystonefinancial/

🔔 Stay tuned for more stock market news, analysis, and investing insights.

Видео Strong Profits, Stronger Growth – Cipher Pharmaceutical (CPH:TSX) Soars Nearly 300% | $CPH канала KeyStone Financial